Metal-drug self-delivery nanomedicine alleviates tumor immunosuppression to potentiate synergistic chemo/chemodynamic therapy against hepatocellular carcinoma
KeAi Communications Co., Ltd.This study developed a metal-drug self-delivery nanomedicine (FDAH) to enhance chemotherapy/chemodynamic therapy for hepatocellular carcinoma (HCC). Leveraging a core of iron-based nanoparticles co-loaded with two clinical drugs, Doxorubicin (DOX) and Plerixafor (AMD3100), and an outer shell of hyaluronic acid (HA), the system enables targeted drug delivery and combats therapeutic resistance. After intravenous administration, the HA shell prolongs blood circulation, facilitating tumor accumulation via the EPR effect and subsequent cellular uptake through HA/CD44-specific interactions. Inside tumor cells, the iron ions mediate chemodynamic therapy by triggering the Fenton reaction to generate reactive oxygen species (ROS), which disrupts redox homeostasis and sensitizes cells to DOX. Simultaneously, AMD3100 blocks the CXCL12/CXCR4 axis to alleviate immunosuppression and enhance chemotherapeutic efficacy. This work demonstrates that targeting the immunosuppressive microenvironment with a CXCR4-inhibiting nanoplatform can effectively synergize chemotherapy and chemodynamic therapy for improved HCC treatment.
- Journal
- Fundamental Research
- Funder
- Beijing Natural Science Foundation, National Natural Science Foundation of China, Guangdong Basic and Applied Basic Research Foundation, Scientific and Technological Innovation Project of China Academy of Chinese Medical Sciences, Science and Technology Program of Guangzhou